Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUSYKG)

• Drug Name: AR-129330 Drug Info
• Synonyms: CHEMBL193438; CHEMBL537846; SCHEMBL3938380; SCHEMBL3941081; SCHEMBL3938377; CHEMBL1188966; NWUCPBLQECHRFK-QAQDUYKDSA-N; BDBM50170189; BDBM50166555; trans-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide; 4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9895867
  TTD Drug ID: DMUSYKG

Molecule-Related Drug Atlas

Drug(s) Targeting Melanin-concentrating hormone receptor 1 (MCHR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-830216	DMCW71N	Obesity	5B81	Phase 1	[2]
AZD1979	DMQ1OX4	Obesity	5B81	Phase 1	[3]
PMID25522065-Compound-27	DMXN4KB	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-29	DMBNAK9	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-34	DMZDIRQ	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-39	DM5YMQH	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-40	DMCIQ01	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-11	DM410Z6	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-50	DMBWA0V	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-12	DMVKO9C	N. A.	N. A.	Patented	[4]

Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[5]
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[6]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[7]
Guanfacine	DMPN5IH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[8]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[9]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[10]
DSP-1200	DM4WSHG	Depression	6A70-6A7Z	Phase 1	[11]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[12]
NMI-870	DMU596F	Sexual dysfunction	HA00-HA01	Discontinued in Phase 2	[13]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[14]

Drug(s) Targeting Neuropeptide Y receptor type 5 (NPY5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CGP71683A	DMRYC08	Obesity	5B81	Discontinued in Phase 3	[15]
Velneperit	DMROSHN	Obesity	5B81	Discontinued in Phase 2	[16]
S-234462	DM80P4U	Obesity	5B81	Discontinued in Phase 1	[16]
Axovan-3	DM1JN6A	Eating disorder	6B82	Discontinued in Phase 1	[17]
FR-79620	DMXR287	Diabetic complication	5A2Y	Preclinical	[18]
GW-594884A	DMHUD27	Obesity	5B81	Preclinical	[18]
NPY5RA-972	DMXUCSN	Obesity	5B81	Preclinical	[18]
RWJ-49815	DMUGZMO	Fungal infection	1F29-1F2F	Terminated	[17]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]	DMKANOH	Discovery agent	N.A.	Investigative	[19]
S-25585	DMBUD1M	Eating disorder	6B82	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-2A (ADRA2A)	TTWG9A4	ADA2A_HUMAN	Inhibitor	[1]
Melanin-concentrating hormone receptor 1 (MCHR1)	TTX4RTB	MCHR1_HUMAN	Inhibitor	[1]
Neuropeptide Y receptor type 5 (NPY5R)	TTY6EWA	NPY5R_HUMAN	Inhibitor	[1]

References

• [1] Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
• [2] 2011 Pipeline of Bristol-Myers Squibb.
• [3] Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
• [4] Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [7] alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
• [8] Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
• [9] Clinical pipeline report, company report or official report of Klus Pharma
• [10] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [13] Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
• [14] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [15] Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
• [16] Clinical pipeline report, company report or official report of Shionogi (2011).
• [17] Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
• [18] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [19] Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.